SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE
Approval overview SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 216885 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE Form and strength TABLET;FILM COATED - 1000MG Sponsor PRINSTON PHARMACEUTICAL INC Submission history Latest submission status date: 2025-03-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 216885 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE Form and strength TABLET;FILM COATED - 1000MG Sponsor PRINSTON PHARMACEUTICAL INC Submission history Latest submission status date: 2025-03-13 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.